Newsroom

Sorted by: Latest

-

European Enterprises Face Growing Pressure to Turn AI Investment into Business Value, ISG Says

PARIS--(BUSINESS WIRE)--The ISG AI Impact Summit will explore operating models and data and governance frameworks to scale AI, November 9–10 at the Pullman Paris Tour Eiffel....
-

Omdia: Global tablet shipments fall 23% to 32 million in Q3 2026

LONDON--(BUSINESS WIRE)--The global tablet market fell 23% year-over-year (YoY) to 32 million units in Q3 2026, marking its lowest shipment level in nearly three years, according to Omdia’s latest research. The Middle East, China and Western Europe were the hardest-hit regions, experiencing sharper declines than the rest of the market. "Following a 10% decline last quarter, the tablet market recorded another double-digit contraction in Q3," said Himani Mukka, Research Manager at Omdia. "As supp...
-

Les entreprises européennes subissent une pression croissante pour transformer leurs investissements dans l’IA en valeur commerciale, selon ISG

PARIS--(BUSINESS WIRE)--Les entreprises européennes subissent une pression croissante pour transformer l’adoption de l’IA en valeur commerciale mesurable, alors qu’une nouvelle étude d’Information Services Group (ISG) (Nasdaq : III), un cabinet mondial de recherche et de conseil en technologies centré sur l’IA, révèle que les performances et l’adoption de l’IA dépassent les attentes, mais que les retombées commerciales et financières sont à la traîne. Les stratégies visant à faire sortir l’IA d...
-

Amazon Music illumine le temps des Fêtes avec de nouvelles chansons originales et exclusives d'artistes du monde entier, dont Elton John et CMAT avec une nouvelle version de « Step Into Christmas »

TORONTO--(BUSINESS WIRE)--Aujourd'hui, Amazon Music dévoile sa nouvelle programmation mondiale de chansons originales exclusives des Fêtes d'artistes du monde entier, dont Elton John et CMAT avec une nouvelle version de « Step Into Christmas (Amazon Music Original) ». Les festivités de cette année comprennent également de remarquables interprétations de classiques des Fêtes et de nouvelles compositions originales de The Beaches, The Head And The Heart, entre autres, ainsi que de nouvelles colle...
-

Reputation’s 2026 UK Automotive Industry Rankings Reveal New Entrants Outscoring Premium Brands on Customer Trust

LONDON--(BUSINESS WIRE)--Reputation, the global leader in reputation intelligence, today released its 2026 UK Automotive Industry Rankings, which recognise the OEMs, AM100 dealer groups and dealerships earning the most trust from UK car buyers. Reputation’s UK Automotive Report ranks the nation’s leading car brands by Reputation Score, a single measure of how customers experience, discuss and rate a business online. Brands at the top of the rankings stand out for earning consistent trust from c...
-

Diplomacy, Business, Innovation : SIAL Paris 2026 at the Heart of Global Food Challenges

PARIS--(BUSINESS WIRE)--305,000 professionals, 8,000 exhibitors and 192 countries and regions represented: SIAL Paris reaffirms its role as a global platform for influence, business and food innovation. Held under the High Patronage of the President of the French Republic, SIAL Paris closed its doors on October 21 after five days that made Paris the centre of gravity for the global food industry. A meeting of G7 Agriculture Ministers, India as Country of Honour and food sovereignty were among t...
-

DIPLOMATIE, BUSINESS, INNOVATION : SIAL PARIS 2026 AU COEUR DES ENJEUX ALIMENTAIRES MONDIAUX

PARIS--(BUSINESS WIRE)--Les enjeux et temps forts de cette édition SIAL Paris 2026...
-

赜灵生物宣布啟動馬來酸氟諾替尼治療骨髓纖維化的國際隨機研究,並將於2026年美國血液學會(ASH)年會上發表相關研究成果

中國,成都--(BUSINESS WIRE)--(美國商業資訊)-- 成都赜灵生物医药科技股份有限公司(赜灵生物/Zenitar)正在開發的馬來酸氟諾替尼(FM)是一種首創的口服JAK2/FLT3/CDK6抑制劑,用於治療骨髓增生性腫瘤(MPN),包括骨髓纖維化(MF)和真性紅血球增多症(PV)。 Zenitar在美國、加拿大和巴西啟動了隨機II期臨床試驗FM-MF-02(NCT07750574),旨在為JAK抑制劑初治和難治性MF患者選擇III期臨床試驗劑量。隨機試驗FMF-02(NCT06457425)已達到第24週研究終點:與蘆可替尼相比,FM 50mg和100mg兩個劑量組在SVR35和TSS50方面均表現更佳,先前的資料已在美國血液學會2024年會(#486)和2025年會(#908)上進行口頭報告。在2026年ASH年會上,Zenitar將公布FMF-02研究的長期追蹤結果(口頭報告,#411,12月12日下午4:30)和難治性PV II期資料(海報展示,#3765,12月13日下午6:00),兩項報告均歸屬於ASH第634專題。 「自蘆可替尼首次獲得FDA批准以來的15年...
-

赜灵生物宣布启动马来酸氟诺替尼治疗骨髓纤维化的国际随机研究,并将在2026年美国血液学会(ASH)年会上公布相关研究成果

中国,成都--(BUSINESS WIRE)--(美国商业资讯)-- 成都赜灵生物医药科技股份有限公司(赜灵生物/Zenitar)正在开发马来酸氟诺替尼(flonoltinib maleate,FM)。FM是一款同类首创的口服JAK2/FLT3/CDK6抑制剂,旨在治疗骨髓增殖性肿瘤(MPN),包括骨髓纤维化(MF)和真性红细胞增多症(PV)。 Zenitar已在美国、加拿大和巴西启动Ⅱ期随机研究FM-MF-02(NCT07750574),旨在为后续针对既往未接受过JAK抑制剂(JAKi)治疗的MF患者及难治性MF患者开展的Ⅲ期研究确定剂量。随机研究FMF-02(NCT06457425)已达到第24周研究终点:FM 50毫克和100毫克剂量组在脾脏体积缩小至少35%的应答率(SVR35)和总症状评分降低至少50%的应答率(TSS50)方面均优于芦可替尼。此前的数据已分别在2024年和2025年美国血液学会(ASH)年会上以口头报告形式公布,摘要编号分别为486和908。在2026年ASH年会上,Zenitar将公布FMF-02研究的长期随访结果(口头报告,摘要编号411,12月12日下...
-

Discover Network and Diners Club International Announce Strategic Payments Partnership with Merlin Entertainments to Enhance Visitor Experience

LONDON & RIVERWOODS, Ill.--(BUSINESS WIRE)--Discover® Network, Diners Club International® and Merlin Entertainments today announced a comprehensive partnership designed to provide seamless payment experiences for millions of guests at some of their most iconic London attractions, as well as across their entire worldwide portfolio. Merlin Entertainments, the global family of destinations, experiences and attractions, has been dedicated to accelerating growth by building deeper guest relationship...